Objective To investigate the risk factors for posthepatectomy liver failure ( PHLF) in patients with hepatocellular carcinoma ( HCC) and to provide a theoretical basis for the prediction and prevention of PHLF. Methods A meta-analysis was performed on the studies on risk factors for PHLF in HCC patients published in China from January 1990 to June 2013 by searching SinoMed, VIP, CNKI, and Wanfang Data and manual retrieval of related articles and references. Results A total of 11 studies involving 2859 patients treated with hepatectomy were included in the meta-analysis. The incidence of PHLF was significantly lower in Child-Pugh A patients than in the control group ( pooled OR = 6. 28, 95% CI: 4. 55-8. 65) . Patients with prealbumin levels less than 170 mg /dl had an increased incidence of PHLF ( pooled OR = 4. 96, 95% CI: 3. 03-8. 10) . Patients with cirrhosis had a higher incidence of PHLF than those without cirrhosis ( pooled OR = 4.14, 95%CI: 2.46-6.98) . Patients with an intraoperative blood loss less than 1000 ml had a lower incidence of PHLF than the control group ( pooled OR = 5. 62, 95% CI: 3. 46-9. 11) . The incidence of PHLF was lower in patients with a tumor diameter less than 10 cm and patients with an extent of resection less than hepatectomy than in the control group ( pooled OR = 2. 69, 95% CI: 1. 58-4. 57; pooled OR = 1. 64, 95% CI: 1. 12-2. 40) . Age ≥60 years and intraoperative blood transfusion increased the incidence of PHLF ( pooled OR = 1.73, 95% CI: 1.25-2.39; pooled OR = 3.79, 95% CI: 2.20-6.51) . Sex and hepatic inflow occlusion were not significantly associated with the development of PHLF ( P > 0. 05) Conclusion Advanced age, advanced preoperative Child-Pugh class, low prealbumin level, high intraoperative blood loss, large tumor diameter, large extent of hepatectomy, cirrhosis, and intraoperative blood transfusion are risk factors for the development of PHLF.
[1]van DEN BROEK MA, OLDE DAMINK SW, DEJONG CH, et al.Liver failure after partial hepatic resection:definition, pathophysiology, risk factors and treatment[J].Liver Int, 2008, 28 (6) :767-780.
|
[2]WANG SG, MA CL, LU Y, et al.Risk factor analysis and treatment for hepatic failure after hepatectomy for primary liver cancer[J].Shanxi J Med, 2007, 36 (6) :691-693. (in Chinese) 王守光, 马长林, 卢云, 等.原发性肝癌肝切除术后肝功能衰竭的相关因素分析及防治[J].陕西医学杂志, 2007, 36 (6) :691-693.
|
[3]CHEN GH.Clinical analysis of hepatic failure after hepatectomy for primary liver cancer[D].Zhejiang:Zhejiang University College of Medicine, 2008. (in Chinese) 陈刚红.原发性肝癌术后肝功能衰竭的临床因素分析[D].浙江:浙江大学医学院, 2008.
|
[4]CHEN XT, ZHAI J, ZHANG YJ, et al.The risk factors of posthepatectomy liver failure for hepatocellular carcinoma in patients of Child-Pugh A[J].J Hepatobiliary Surg, 2012, 20 (3) :170-173. (in Chinese) 陈绪涛, 翟健, 张一军, 等.Child-Pugh A级肝细胞癌患者术后肝功能衰竭发生的危险因素分析[J].肝胆外科杂志, 2012, 20 (3) :170-173.
|
[5]HU SQ, HE J, YU Y, et al.Influence factors for acute liver failure after hepatectomy of primary hepatic carcinoma[J].J Guangxi Coll Tradit Chin Med, 2010, 13 (3) :8-10. (in Chinese) 胡嗣钦, 赫军, 俞渊, 等.原发性肝癌术后急性肝功能衰竭影响因素分析[J].广西中医学院学报, 2010, 13 (3) :8-10.
|
[6]SUN ZD, JIANG Y, ZHU F, et al.Clinical analysis of hepatic failure after hepatectomy for liver cancer associated with cirrhosis[J].J Hepatopancreatobiliary Surg, 2010, 22 (6) :463-465. (in Chinese) 孙振棣, 江勇, 朱峰, 等.原发性肝癌合并肝硬化肝切除术后肝功能衰竭的临床分析[J].肝胆胰外科杂志, 2010, 22 (6) :463-465.
|
[7]WEI JB, CHEN SR, PU J, et al.Analysis on risk factors leading incomplete compensation of liver function after hepatectomy for primary liver cancer[J].J Hepatobiliary Surg, 2005, 13 (6) :424-468. (in Chinese) 韦建宝, 陈山荣, 浦涧, 等.肝癌切除术后肝功能代偿不全的危险因素分析[J].肝胆外科杂志, 2005, 13 (6) :424-468.
|
[8]DU GJ, WU LQ, ZHU CZ, et al.Predictive factors for liver dysfunction and failure after hepatectomy:analysis of 467 patients with hepatocellular carcinoma[J].Chinese-German J Clinical Oncol, 2012, 11 (4) :210-213.
|
[9]HUANG L, LI J, YAN JJ, et al.Prealbumin is predictive for postoperative liver insufficiency in patients undergoin liver resection[J].World J Gastroenterol, 2012, 18 (47) :7021-7025.
|
[10]LIU YH, ZHENG XL, ZHENG Z, et al.Perioperative risk factors for liver failure after hepatectomy of primary hepatic carcinoma[J].Chin Gen Pract, 2013, 16 (6) :2036-2038. (in Chinese) 柳已海, 郑小林, 郑直, 等.原发性肝癌肝切除术后患者发生肝功能衰竭的围术期危险因素分析[J].中国全科医学, 2013, 16 (6) :2036-2038.
|
[11] XU YX, JIN L, LU WJ, et al.Risk factor analysis and treatment for hepatic failure after hepatectomy for primary liver cancer[J].Changzhou Pract Med, 2013, 29 (4) :217-219. (in Chinese) 徐逸昕, 金雷, 陆维军, 等.原发性肝癌切除术后肝功能衰竭的临床分析[J].常州实用医学, 2013, 29 (4) :217-219.
|
[12]XIONG BW, HOU K.Risk factors of the perioperative liver failure after hepatectomy[J].J Chin Modern Med, 2013, 20 (25) :12-16. (in Chinese) 熊邦文, 侯琨.原发性肝癌肝切除后发生肝功能衰竭的围术期相关危险因素[J].中国当代医药, 2013, 20 (25) :12-16.
|
[13]IAKOVA P, AWAD SS, TIMCHENKO NA.Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest[J].Cell, 2003, 113 (4) :495-506.
|
[14]YOKOYAMA YY, SCHWACHA MG, SAMY TS, et al.Gender dimorphism in immune responses following trauma and hemorrhage[J].Immunol Res, 2002, 26 (1-3) :63-76.
|
[15]ZENG DX, LIN M, CHUN X.The clinical significance of detection of serum prealbumin in patients with hepatopathy[J].The J Med Theory Pract, 2010, 23 (11) :1314-1315. (in Chinese) 曾东晓, 林梅, 春祥.肝病患者血清前自蛋白检测的临床价值分析[J].医学理论与实践, 2010, 23 (11) :1314-1315.
|
[16]FANG ML.Prognostic values of serum prealbumin and alpha-fetoprotein levels in patients with severe hepatitis[J].J Clin Exp Med, 2012, 11 (18) :1509-1510. (in Chinese) 方美丽.血清前白蛋白及甲胎蛋白水平在预测重型肝炎患者转归中的价值[J].临床和实验医学杂志, 2012, 11 (18) :1509-1510.
|
[17]AWAD S, CONSTANTIN-TEODOSIU D, MACDONALD IA, et al.Short-term starvation and mitochondrial dysfunction–a possible mechanism leading to postoperative insulin resistance[J].Clin Nutr, 2009, 28 (5) :497-509.
|
[18]IMAMURA H, SEYAMA Y, KOKUDO N, et al.One thousand fifty-six hepatectomies without mortality in 8 years[J].Arch Surg, 2003, 138 (11) :1198-1206.
|
[19]EGNCHI S, IJTSMA AJ, SLCOFF MJ, et al.Outcome and pattern of recurrerlee after curative resection for hepatocellular carcinoma in patients with a normal liver compared to patients with a diseased liver[J].Hepatogastroenterology, 2006, 53 (70) :592-596.
|
[20]TIBERIO GA, TIBERIO L, BENETTI A, et al.IL-6 promotes compensatory liver regeneration in cirrhotic rat liver after partial hepatectomy[J].Cytokine, 2008, 42 (3) :372-378.
|
[21]POON RT, FAN ST, LO CM, et al.Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis:is it justified?[J].Ann Surg, 2002, 236 (5) :602-611.
|
[22]LEE SG, HWANG S.How I do it:assessment of hepatic functional reserve for indication of hepatic resection[J].J Hepatobiliary Pancreat Surg, 2005, 12 (1) :38-43.
|
[23]HUANG CY, HUANG JF, CHEN YL, et al.The surgical treatment of primary hepotacellular carcinoma with tumor thrombi in portal vein[J].J Hepatobiliary Surg, 2005, 13 (6) :253-255. (in Chinese) 黄长玉, 黄建富, 陈燕凌, 等.原发性肝细胞癌合并门静脉癌栓的外科治疗[J].肝胆外科杂志, 2005, 13 (6) :253-255.
|
[24]YUAN JL, LIU CH, ZHAO CQ.Studies on relevant gactors of Child-Pugh grading inhepatic cirrhosis[J].J Clin Hepatol, 2011, 27 (3) :270-272. (in Chinese) 袁继丽, 刘成海, 赵长青.肝硬化Child-Pugh评分的相关因素分析[J].临床肝胆病杂志, 2011, 27 (3) :270-272.
|
1. | 丁辉,苏雪梅,张蓉. 子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究. 现代检验医学杂志. 2025(01): 122-126+131 . ![]() | |
2. | 王慧敏,谭炳芹,王万鹏,吴梦雪. 慢性乙型肝炎病毒感染相关肝病患者血清高尔基体蛋白73水平变化分析. 山东医药. 2025(01): 100-103+108 . ![]() | |
3. | 张璨,张欢欢,高飞,任佩佩,罗明阳,闫冬,王馨,王莹莹,曾艳丽. 血清高尔基体蛋白73联合肝脏硬度评估慢性乙型肝炎病毒感染患者肝纤维化进展的价值. 中华实用诊断与治疗杂志. 2024(10): 1013-1018 . ![]() | |
4. | 李述美,刘冰,刘仁伟,杨洁. GP73、IL-2R、miR-21预测慢性乙肝患者显著肝纤维化的临床价值. 重庆医学. 2024(23): 3575-3580 . ![]() | |
5. | 安薪宇,乔杰,胡灵溪,王荣琦,南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 . ![]() | |
6. | 张航,刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2023(03): 657-662 . ![]() | |
7. | 马杨青,范海纳,孙鑫,刘成海. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值. 临床肝胆病杂志. 2023(08): 1999-2004 . ![]() | |
8. | 张欢,雷学忠. 新型血清标志物高尔基体蛋白73在慢性乙型肝炎临床诊治中的研究进展. 华西医学. 2023(08): 1243-1246 . ![]() | |
9. | 陈腾千,姜丽华,张生君,蒋义贵,罗佳,胡永敏,尤丽财. 高尔基体蛋白73在非酒精性脂肪性肝病中的应用价值. 黑龙江医学. 2023(17): 2053-2055+2059 . ![]() | |
10. | 李雨蓉,姚明解,王杰. 序贯无创检测提高肝纤维化筛查效率. 肝脏. 2023(10): 1146-1149 . ![]() | |
11. | 刘燕娜,姚明解,郑素军,陈香梅,刘向祎,胡鹏,欧启水,窦晓光,陈红松,段钟平,侯金林,南月敏,高志良,徐小元,庄辉,鲁凤民. 血清高尔基体蛋白73在慢性肝病患者中的临床应用. 中华肝脏病杂志. 2022(01): 4-8 . ![]() | |
12. | 裴倩云,孙颖. 血清免疫球蛋白检验在肝衰竭患者的诊断价值. 系统医学. 2022(15): 103-105+118 . ![]() | |
13. | 王鹏飞,刘树红,钱相君,翟相威,文夏杰,姚明解,赵景民,鲁凤民. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究. 中华肝脏病杂志. 2022(08): 879-884 . ![]() | |
14. | 郑伟明,罗翠转,卢金英,骆晓豪,刘浩,梁栋伟. 血过氧化物酶增殖体激活受体γ与慢性乙型肝炎患者炎症的相关性. 中国肝脏病杂志(电子版). 2022(04): 42-47 . ![]() | |
15. | 庄云英,张海燕,曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展. 肝脏. 2021(01): 84-87 . ![]() | |
16. | 刘燕娜,姚明解,鲁凤民. 慢性肝病患者中血清高尔基体蛋白73的临床应用. 肝脏. 2021(02): 103-106 . ![]() | |
17. | Application of serum Golgi protein-73 in the management of chronic liver disease. 中华医学杂志英文版. 2021(07): 777-779 . ![]() | |
18. | 罗双艳,何颖. 慢性乙肝患者肝脏炎症及纤维化的影响因素及其与血清高尔基体蛋白73的相关性. 医学信息. 2021(15): 5-8 . ![]() | |
19. | 高伟,高虹,尹春梅,杨森林,范晓红,刘春亮,李雪卿,贾妮娜. 血清GP73与p62测定对HBV相关慢加急性肝衰竭患者短期预后的预测价值比较. 中华肝脏病杂志. 2021(09): 855-860 . ![]() | |
20. | 王一奇,苑喜微,李冬冬,汤玉会,薛宁宁,崔璐瑶,刘领弟,南月敏. 血浆高尔基体蛋白73及相关模型诊断非酒精性脂肪性肝病的研究. 中华肝脏病杂志. 2021(12): 1170-1176 . ![]() | |
21. | 张春林. 患儿脓毒症继发肝损伤的危险因素及血清高尔基体跨膜糖蛋白73、微小RNA-122a水平变化. 中国临床医生杂志. 2020(02): 236-238 . ![]() | |
22. | 刘沁雨,常越,张青,丁玉平,李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 . ![]() | |
23. | 翟相威,刘树红,姚明解,钱相君,文夏杰,许强,赵景民,鲁凤民. 基于血清高尔基体蛋白73的代偿期乙型肝炎肝硬化无创诊断模型的建立及初步应用. 中华肝脏病杂志. 2020(01): 47-52 . ![]() | |
24. | 范旭,单珊,刘立伟,贾继东. 血清高尔基糖蛋白73优于APRI、FIB-4对慢性HBV感染患者显著纤维化的诊断. 现代消化及介入诊疗. 2020(04): 529-532 . ![]() | |
25. | 范旭,单珊,刘立伟,贾继东. 血清高尔基体跨膜糖73蛋白及其他生物标志物联合检测在AFP阴性小肝癌诊断中的意义. 现代消化及介入诊疗. 2020(04): 435-439+443 . ![]() | |
26. | 刘沁雨,常越,张文,张青,卢诚震,李海. GP73预测慢性乙型肝炎患者肝硬化进展研究. 武警医学. 2020(04): 317-323 . ![]() | |
27. | 马玲玉,甄一宁,罗云萍,段昭君. gp73在小鼠肝纤维化肝组织中的表达及机制. 基础医学与临床. 2020(06): 771-776 . ![]() | |
28. | 刘沁雨,常越,张青,丁玉平,李海. 血清GP73与PYGO2对已长期抗病毒治疗慢性乙型肝炎肝硬化的诊断价值. 山东医药. 2020(29): 64-66 . ![]() | |
29. | 李佳娜,郑瑞琦,李娜,胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值. 临床肝胆病杂志. 2019(06): 1361-1364 . ![]() | |
30. | 王春艳,纪冬,马丽君,陈松海,王晶晶,邵清,陈国凤,韩萍. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性. 解放军医学杂志. 2019(06): 503-507 . ![]() | |
31. | 宋莹,李世朋,焦伟伟. 血清HMGB1、TGFβ1及GP73检测对脓毒症并发肝损伤预后的评估价值. 分子诊断与治疗杂志. 2019(06): 457-461 . ![]() |